New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareDecapeptide-12 vs Cartalax

Decapeptide-12 vs Cartalax

Side-by-side comparison of key properties, dosing, and research.

Skin & Cosmetic
Decapeptide-12
Anti-Aging & Longevity
Cartalax
Summary
Decapeptide-12 is a synthetic 10-amino acid peptide developed for skin brightening and depigmentation. It selectively inhibits tyrosinase activity and downstream melanogenesis pathways, reducing hyperpigmentation, dark spots, and uneven skin tone without the irritation associated with hydroquinone.
Cartalax is a tetrapeptide bioregulator (Ala-Glu-Asp-Pro) developed by Professor Vladimir Khavinson for cartilage and connective tissue. It is tissue-specific for chondrocytes and cartilaginous structures, supporting cartilage matrix synthesis, slowing degenerative changes, and promoting joint longevity. It is used in the context of osteoarthritis, joint aging, and athletic cartilage preservation.
Half-Life
Not applicable (topical)
Short (minutes); gene-regulatory effects are sustained
Admin Route
Topical
SubQ, Oral
Research
Typical Dose
5 ppm (0.0005%) concentration
10 mg per day
Frequency
Twice daily (AM and PM)
Daily for 10–30 days
Key Benefits
  • Reduces hyperpigmentation and dark spots
  • Evens skin tone and improves radiance
  • Inhibits post-inflammatory hyperpigmentation
  • Well-tolerated alternative to hydroquinone
  • Effective for melasma and age spots
  • Non-cytotoxic to melanocytes
  • Supports cartilage matrix synthesis and maintenance
  • May slow progression of osteoarthritic cartilage degradation
  • Reduces chondrocyte apoptosis
  • Promotes joint longevity in aging and high-impact sports
  • Anti-aging effects on connective tissue
  • Complementary to BPC-157 and TB-500 in joint recovery protocols
  • Well tolerated in available human and animal research
Side Effects
  • Generally very well-tolerated
  • Rare mild irritation or sensitivity in some skin types
  • Results may take several weeks to become visible
  • Generally well tolerated
  • Mild injection site reactions
  • No significant adverse events reported at standard doses
Stacks With